long PD-L1 peptide vaccine

Long PD-L1 peptide vaccine is an investigational 19-amino-acid peptide cancer vaccine derived from programmed cell death ligand 1 and comprising the sequence FMTYWHLLNAFTVTVPKDL. It is intended to elicit PD-L1-specific CD4-positive and CD8-positive T-cell responses against PD-L1-expressing immunosuppressive and malignant cells. In the completed Phase I-II MPN study NCT04051307, PD-L1Long was administered subcutaneously with Montanide ISA-51 as adjuvant as part of a dual-peptide vaccination regimen for mutation-positive polycythemia vera and essential thrombocythemia. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/long-pd-l1-peptide-vaccine))

Other names

PD-L1 Long (19-27) peptidePD-L1 long (19-27) peptide vaccinePD-L1 long peptide vaccinePD-L-1 long peptide vaccinePD-L 1 long peptide vaccinePD-L1 long vaccinePD-L-1 long vaccinePD-L 1 long vaccinePD-L1LongPD-L-1LongPD-L 1LongPD-L1Long1PD-L-1Long1PD-L 1Long1